clinical trial results
Arcturus Therapeutics Stock Crashes 60% on Underwhelming mRNA Cystic Fibrosis Drug Results
Arcturus Therapeutics; ARCT-032; cystic fibrosis; mRNA therapy; stock crash; clinical trial results; lung function; FEV1; safety profile